These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29422022)

  • 21. [The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness].
    Schlander M; Trott GE; Schwarz O
    Nervenarzt; 2010 Mar; 81(3):289-300. PubMed ID: 20232510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
    Birnbaum HG; Kessler RC; Lowe SW; Secnik K; Greenberg PE; Leong SA; Swensen AR
    Curr Med Res Opin; 2005 Feb; 21(2):195-206. PubMed ID: 15801990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Attention-deficit/hyperactivity disorder in childhood/adolescence and impairments associated with daily life: French data from the European Lifetime Impairment Survey].
    Caci H; Paillé S
    Arch Pediatr; 2014 Dec; 21(12):1283-92. PubMed ID: 25300717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case.
    Le HH; Hodgkins P; Postma MJ; Kahle J; Sikirica V; Setyawan J; Erder MH; Doshi JA
    Eur Child Adolesc Psychiatry; 2014 Jul; 23(7):587-98. PubMed ID: 24166532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis.
    Libutzki B; Ludwig S; May M; Jacobsen RH; Reif A; Hartman CA
    Eur Psychiatry; 2019 May; 58():38-44. PubMed ID: 30802682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity.
    Ray GT; Levine P; Croen LA; Bokhari FA; Hu TW; Habel LA
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1063-9. PubMed ID: 17018466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.
    Braun S; Russo L; Zeidler J; Linder R; Hodgkins P
    Clin Ther; 2013 May; 35(5):673-85. PubMed ID: 23587606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.
    Doshi JA; Hodgkins P; Kahle J; Sikirica V; Cangelosi MJ; Setyawan J; Erder MH; Neumann PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Oct; 51(10):990-1002.e2. PubMed ID: 23021476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.
    Secnik K; Swensen A; Lage MJ
    Pharmacoeconomics; 2005; 23(1):93-102. PubMed ID: 15693731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: qualitative synthesis of scientific evidence.
    Catalá-López F; Ridao M; Sanfélix-Gimeno G; Peiró S
    Rev Psiquiatr Salud Ment; 2013; 6(4):168-77. PubMed ID: 23453596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional consequences of attention-deficit hyperactivity disorder on children and their families.
    Usami M
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):303-17. PubMed ID: 27061213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder.
    Guevara J; Lozano P; Wickizer T; Mell L; Gephart H
    Pediatrics; 2001 Jul; 108(1):71-8. PubMed ID: 11433056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parent-Reported Health Consequences and Relationship to Expenditures in Children with ADHD.
    deJong NA; Williams CS; Thomas KC
    Matern Child Health J; 2016 Apr; 20(4):915-24. PubMed ID: 26754346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The economic burden of adult attention deficit hyperactivity disorder: A sibling comparison cost analysis.
    Daley D; Jacobsen RH; Lange AM; Sørensen A; Walldorf J
    Eur Psychiatry; 2019 Sep; 61():41-48. PubMed ID: 31288209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
    Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P;
    BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economic costs of childhood disability.
    Stabile M; Allin S
    Future Child; 2012; 22(1):65-96. PubMed ID: 22550686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
    Sohn M; Talbert J; Moga DC; Blumenschein K
    Atten Defic Hyperact Disord; 2016 Sep; 8(3):149-58. PubMed ID: 27143026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The prevalence of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)].
    Schlack R; Hölling H; Kurth BM; Huss M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007; 50(5-6):827-35. PubMed ID: 17514469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
    Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
    Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.